A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
To demonstrate whether addition of MM-121 to paclitaxel is more effective than treatment with
paclitaxel alone, when administered as part of the neoadjuvant treatment in Her2 negative
locally advanced operable breast cancer patients.